Sandoz Logo Sandoz Blue RGB_adjusted.png
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
22 janv. 2024 01h00 HE | Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE CIMERLI®*, a ranibizumab biosimilar, is interchangeable with LUCENTIS®**...
Sandoz Logo Sandoz Blue RGB_adjusted.png
Sandoz launches Hyrimoz® (adalimumab) high-concentration formulation in Europe, aiming to improve patient care
21 nov. 2023 01h00 HE | Sandoz Group
Biosimilar Hyrimoz® (adalimumab) citrate-free high-concentration formulation (HCF) indicated for all conditions of reference medicine Humira®* Hyrimoz® HCF to launch progressively across...
Sandoz+logo-OCT+2.png
Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany
10 nov. 2023 08h02 HE | Sandoz Group
Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicinesNew penicillin production process will significantly improve ecological footprint and help...
Sandoz+logo-OCT+2.png
Sandoz successfully issues EUR 2.0 billion inaugural Eurobonds
08 nov. 2023 12h46 HE | Sandoz Group
NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN  Inaugural Eurobonds priced earlier today; three tranches of EUR 700 million, EUR 700 million and EUR 600...
Sandoz+logo-OCT+2.png
Sandoz successfully issues CHF 750 million in inaugural bonds
26 oct. 2023 11h45 HE | Sandoz Group
Highly successful inaugural CHF senior bonds priced earlier todayTwo tranches of CHF 400 million and CHF 350 million with maturities of 3 and 8 years, carrying 2.125% and 2.600% fixed coupons,...
Sandoz+logo-OCT+2.png
Sandoz reports year-to-date sales for the first nine months of 2023
24 oct. 2023 01h15 HE | Sandoz Group
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Nine-month net sales1 of USD 7.1 billion, up 6 percent in constant currencies (cc)(1)Solid performance in Generics;...
Sandoz+logo-OCT+2.png
Sandoz enters new era as standalone global leader and European champion in generic and biosimilar medicines
04 oct. 2023 01h05 HE | Sandoz Group
Spin-off from Novartis successfully completed with first trading day today on SIX Swiss Exchange; Sandoz shares included in key market indicesStandalone Sandoz committed to extend leadership in stable...